Filing Flows

Filing Flows › 8-K events › Axogen

Axogen: results of operations

Form 8-K filed Oct 28, 2026 · items 2.02, 7.01

Results of operationsAxogen, Inc. Reports Third Quarter 2026 Financial Results

What the filing says

Reports Third Quarter 2026 Financial Results Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million

ScaleThe filing names $290.0M: about 96% of Axogen's annual revenue ($303.3M, four times the latest quarter).

Read the filing on SEC EDGAR →

What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Every item ranked →

Axogen at a glance

Latest quarterQ3 2026
Revenue$75.8M
Revenue Y/Y+26%
Operating margin1.3%
IndustryElectromedical & Electrotherapeutic Apparatus

Axogen, Q3 2026: revenue $75.8M (+26% year over year), operating margin 1.3%. The chart follows the revenue to costs, profit and cash.

Axogen: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent guidance

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.